Utility of PTEN, MLH1, ARID1A, Beta-catenin, Bax and BCL-2 biomarkers in endometrial hyperplasia and endometrioid endometrial carcinoma

被引：0
|
作者：
Dover, D. Kosemetin [1 ]
Senol, S. [1 ]
Aydin, A. [1 ]
机构：
[1] Van Bolge Hastanesi, Patol Lab, Edremit Van, Turkey
来源：
VIRCHOWS ARCHIV | 2015年 / 467卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-09-087
引用
收藏
页码：S155 / S155
页数：1
相关论文
共 50 条
  • [41] MMP-2, TIMP-1, E-cadherin, and β-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium
    Shaco-Levy, Ruthy
    Sharabi, Shalom
    Piura, Benjamin
    Sion-Vardy, Netta
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2008, 87 (08) : 868 - 874
  • [42] Immunohistochemical expression of DNA mismatch repair gene products - MLH1 and MSH2, metastasis supression gene nm-23 and beta-catenin in synchronous and metastatic endometrioid adenocarcinomas of ovary and endometrium
    Jones, MW
    Esposito, N
    Kapali, M
    LABORATORY INVESTIGATION, 2006, 86 : 183A - 183A
  • [43] Curcumin down-regulates Ets-1 and Bcl-2 expression in human endometrial carcinoma HEC-1-A cells
    Yu, Ziming
    Shah, Dinesh M.
    GYNECOLOGIC ONCOLOGY, 2007, 106 (03) : 541 - 548
  • [44] Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma -: Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome
    Peiró, G
    Lohse, P
    Mayr, D
    Diebold, J
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 120 (01) : 78 - 85
  • [45] Comparative characteristics of the transcriptional activity of CDH1, CTNNB1, VEGFA genes and expression of proteins E-cadherin, beta-catenin and VEGFA, coded by these genes in metastatic and non-metastatic endometrioid endometrial carcinoma
    Tumanskiy, V. A.
    Chepets, A. V.
    Kamyshnyi, A. M.
    PATHOLOGIA, 2016, (02): : 13 - 18
  • [46] Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)
    Schram, Alison
    Eskander, Ramez
    Sill, Michael
    Hagemann, Andrea
    Waggoner, Steven
    Press, Joshua
    Ghamande, Sharad
    Zivanovic, Oliver
    Bottsford-Miller, Justin
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S56 - S57
  • [47] Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression
    Dudley, Beth
    Brand, Randall E.
    Thull, Darcy
    Bahary, Nathan
    Nikiforova, Marina N.
    Pai, Reetesh K.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (08) : 1114 - 1120
  • [48] Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study
    Lacey, James V., Jr.
    Yang, Hannah
    Gaudet, Mia M.
    Dunning, Alison
    Lissowska, Jolanta
    Sherman, Mark E.
    Peplonska, Beata
    Brinton, Louise A.
    Healey, Catherine S.
    Ahmed, Shahana
    Pharoah, Paul
    Easton, Douglas
    Chanock, Stephen
    Garcia-Closas, Montserrat
    GYNECOLOGIC ONCOLOGY, 2011, 120 (02) : 167 - 173
  • [49] Bcl-2 exerts a pRb-Mediated cell cycle inhibitory function in HEC1B endometrial carcinoma cells
    Crescenzi, E
    Palumbo, G
    GYNECOLOGIC ONCOLOGY, 2001, 81 (02) : 184 - 192
  • [50] Targeted Next-Generation Sequencing of MLH1, MSH2, and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age
    Ozdemir, Taha Resid
    Alan, Murat
    Sanci, Muzaffer
    Koc, Altug
    BALKAN MEDICAL JOURNAL, 2019, 36 (01) : 37 - 42
12345